Biohaven Inks Up To $1.24B Deal For Epilepsy Drug Biz
Clinical-stage biopharmaceutical company Biohaven said Friday it plans to buy a subsidiary of Knopp Biosciences and its business focused on treating epilepsy in a deal worth up to about $1.24 billion,...To view the full article, register now.
Already a subscriber? Click here to view full article